CPRX

Catalyst Pharmaceuticals Inc.

Price

return (12m)

0.00%

p/e

17.36

p/bv

3.79

DIVIDEND YIELD

0.00%

CPRX price

Catalyst Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CPRX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals CPRX

Valuation

P/E

17.36

Sector -5.81

Industry -5.81

P/BV

3.79

Sector 1.45

Industry 1.45

P/Revenue (PSR)

6.44

Sector -5.82

Industry -5.82

EV/EBITDA

12,046,732.25

Sector -58,996,766.14

Industry -58,996,766.14

EV/EBIT

13,655,595.30

Sector -34,683,138.95

Industry -34,683,138.95

P/EBITDA

12.56

Sector -6.08

Industry -6.08

P/EBIT

14.35

Sector -6.03

Industry -6.03

P/Total Assets

3.35

Sector 1.24

Industry 1.24

P/Net Current Assets

1,241,495.75

Sector -10,172,795.43

Industry -10,172,795.43

P/Working Capital

1,237,639.08

Sector -12,104,673.65

Industry -12,104,673.65

EPS

1.81

Sector -3.12

Industry -3.12

BVPS

8.30

Sector 1.33

Industry 1.33

Efficiency

Gross Margin

85.96%

Sector 30.38%

Industry 30.38%

EBITDA Margin

55.57%

Sector -16,743.16%

Industry -16,743.16%

EBIT Margin

49.02%

Sector -4,275,111.13%

Industry -4,275,111.13%

Operating Margin

44.84%

Sector -47.21%

Industry -47.21%

Net Profit Margins

37.08%

Sector -47.95%

Industry -47.95%

Asset Turnover

0.13

Sector 0.03

Industry 0.03

Profitability

ROE

21.85%

Sector -102.69%

Industry -102.69%

ROA

19.29%

Sector -91.11%

Industry -91.11%

ROIC

84.06%

Sector -1,699.17%

Industry -1,699.17%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

7.10

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-9.11

Sector -14.61

Industry -14.61

Net Debt / EBIT

-10.32

Sector -7.15

Industry -7.15

Net Debt / Equity

-0.75

Sector -33,112.88

Industry -33,112.88

Gross Debt / Equity

0.00

Sector -0.48

Industry -0.48

Equity/Assets

0.88

Sector 0.29

Industry 0.29

Liabilities/Assets

0.12

Sector 0.35

Industry 0.35

Growth

5Y Revenue CAGR

1,503.71%

Sector -

Industry -

5Y Earnings CAGR

1,644.19%

Sector -

Industry -

FAIR VALUE OF Catalyst Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.00

Fair Value

$18.39

Upside Return potential.

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals CPRX

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
CPRX	17.36	3.79	21.85%	0.00%	$1,000.00 T	37.08%
JNJ	29.40	7.28	24.76%	2.04%	$618.44 B	21.48%
PFE	18.75	1.55	8.29%	6.97%	$140.44 B	11.83%
ABBV	71.07	0.00	-%	2.66%	$448.43 B	9.80%
NVO	11.00	6.65	60.40%	3.96%	$208.75 B	37.15%
MRK	36.20	7.04	19.45%	2.57%	$323.45 B	13.59%
AZN	25.16	5.22	20.74%	1.89%	$262.79 B	17.02%
GILD	17.55	6.90	39.33%	2.47%	$161.73 B	30.99%
BMY	14.12	5.87	41.59%	3.91%	$131.06 B	18.87%
ZTS	12.23	10.00	81.75%	2.69%	$32.33 B	27.79%
REGN	17.58	2.40	13.65%	0.49%	$76.11 B	27.86%
HALO	27.82	44.19	158.82%	0.00%	$9.70 B	23.13%
AMGN	26.59	22.57	84.87%	2.55%	$207.38 B	20.96%
MCK	22.00	-125.59	-570.98%	0.38%	$104.74 B	1.18%
VRTX	27.75	6.22	22.41%	0.00%	$120.39 B	35.51%
CAH	34.61	-20.14	-58.20%	0.89%	$53.82 B	0.62%
HRMY	13.88	2.22	16.00%	0.00%	$2.02 B	16.20%
BIIB	36.30	1.61	4.43%	0.00%	$30.30 B	8.32%
MEDP	32.46	36.77	113.29%	0.00%	$15.95 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CPRX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (4 people)

United States

20 years

Founded: 2006

2006

Time since IPO - 20 years

74

Employees

Catalyst Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1,000.00 trillion, with shareholders equity totaling $1.01 billion.

The company employs approximately 74 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Catalyst Pharmaceuticals Inc. reported $596.95 million in revenue, generating net income of $221.32 million.

Key financial metrics include a P/E ratio of 17.36, a price-to-book (P/B) ratio of 3.79, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CPRX.

Market cap

$1,000.00 trillion

Net worth

$1.01 billion

$1,012,700,000.00

Assets

$1.15 billion

$1,147,610,000.00

Total Shares Outstanding

122.00 million

122,000,000

Average Daily Trading Volume

$2.60 million

$2,604,028.48

Sector

Health Care

Industry

Biotechnology

CPRX

CPRX revenue and profits

Financial Results CPRX

DRAG THE FRAME TO SEE MORE DATA

CPRX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$859.49 23,49% (12M)

P/E

22.00

0.38%

ROE

-570.98%

P/BV

-125.59

CAH - Cardinal Health

$229.02 48,35% (12M)

P/E

34.61

0.89%

ROE

-58.20%

P/BV

-20.14

JNJ - Johnson & Johnson

$258.25 58,21% (12M)

P/E

29.40

2.04%

ROE

24.76%

P/BV

7.28

ABBV - AbbVie

$253.35 35,07% (12M)

P/E

71.07

2.66%

ROE

P/BV

0.00

MRK - Merck & Co.

$130.85 70,49% (12M)

P/E

36.20

2.57%

ROE

19.45%

P/BV

7.04

AZN - AstraZeneca

$170.49 16,29% (12M)

P/E

25.16

1.89%

ROE

20.74%

P/BV

5.22

NVO - Novo Nordisk

$46.99 0,92% (12M)

P/E

11.00

3.96%

ROE

60.40%

P/BV

6.65

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$859.49 23,49% (12 M)

P/L

22.00

0.38%

ROE

-570.98%

P/VP

-125.59

CAH - Cardinal Health

$229.02 48,35% (12 M)

P/L

34.61

0.89%

ROE

-58.20%

P/VP

-20.14

JNJ - Johnson & Johnson

$258.25 58,21% (12 M)

P/L

29.40

2.04%

ROE

24.76%

P/VP

7.28

ABBV - AbbVie

$253.35 35,07% (12 M)

P/L

71.07

2.66%

ROE

P/VP

0.00

MRK - Merck & Co.

$130.85 70,49% (12 M)

P/L

36.20

2.57%

ROE

19.45%

P/VP

7.04

AZN - AstraZeneca

$170.49 16,29% (12 M)

P/L

25.16

1.89%

ROE

20.74%

P/VP

5.22

NVO - Novo Nordisk

$46.99 0,92% (12 M)

P/L

11.00

3.96%

ROE

60.40%

P/VP

6.65

Frequently Asked Questions

What is the price of Catalyst Pharmaceuticals (CPRX) today?

A cotação de Catalyst Pharmaceuticals (CPRX) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Catalyst Pharmaceuticals (CPRX) iniciou o ano negociando na casa dos US$ 23.34 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Catalyst Pharmaceuticals (CPRX) e dados de ações do Ibovespa e mercados internacionais.

Quando Catalyst Pharmaceuticals (CPRX) paga dividendos?

Catalyst Pharmaceuticals (CPRX) não distribuiu dividendos no último ano.

Is Catalyst Pharmaceuticals (CPRX) a good investment?

Atualmente, Catalyst Pharmaceuticals (CPRX) está cotada a US$ 0.00, com um P/L de 17.36, representando um desvio de 1,897% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Catalyst Pharmaceuticals (CPRX) stock?

Investir em ações de Catalyst Pharmaceuticals (CPRX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Catalyst Pharmaceuticals (CPRX) yield today?

A rentabilidade de Catalyst Pharmaceuticals (CPRX) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Catalyst Pharmaceuticals (CPRX) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CPRX

Catalyst Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CPRX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc.

United States

20 years

2006

74

PROFIT X PRICE CPRX

Financial Results CPRX

CPRX cash flow

Asset, Revenue and Profit Growth - CPRX

CPRX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

NVO - Novo Nordisk

Frequently Asked Questions